Abstract
Calcification is the most frequent cause of the failure of bioprosthetic heart valves fabricated from glutaraldehyde pretreated porcine aortic valves or bovine pericardium. Formulation and evaluation of controlled-release drug delivery system to inhibit bioprosthetic heart valve calcification is reviewed.
Original language | English |
---|---|
Pages (from-to) | 266-289 |
Number of pages | 24 |
Journal | Journal of Biomaterials Applications |
Volume | 2 |
Issue number | 2 |
DOIs | |
State | Published - Apr 1987 |